<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684589</url>
  </required_header>
  <id_info>
    <org_study_id>202420</org_study_id>
    <nct_id>NCT04684589</nct_id>
  </id_info>
  <brief_title>Effect of PDE5 Inhibition on Adipose Metabolism in Humans</brief_title>
  <official_title>Effect of PDE5 Inhibition on Adipose Metabolism in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled study of the effects of PDE5&#xD;
      inhibition with tadalafil on adipose tissue in obese individuals. Adipose metabolism will be&#xD;
      measured using magnetic resonance imaging (MRI) scans and by aspirating a small amount of&#xD;
      adipose to measure gene expression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test whether tadalafil causes subcutaneous adipose tissue to&#xD;
      have a &quot;beige&quot; phenotype. Participants will be randomized to either placebo or tadalafil for&#xD;
      12 weeks. Investigators will study adipose metabolism using MRI scans and aspiration of&#xD;
      subcutaneous adipose from the abdomen. In addition to MRI scans at room temperature, the&#xD;
      investigators will use a cooling protocol to test the combined effects of tadalafil and on&#xD;
      adipose metabolism. Investigators will also measure the effects of the drug on body&#xD;
      composition. In addition to the study visits, participants will wear an activity tracker&#xD;
      (Fitbit) and log their dietary intake several times using an online tool. There will be a&#xD;
      small amount of radiation exposure. Participants will be compensated for participation in&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Half of participants to get tadalafil and half to get placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Thermoneutral FSF of WAT at the level of the umbilicus at 12 Weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>MRI measurement of lipid content</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subcutaneous adipose tissue expression of UCP1 (normalized expression units)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of gene expression in adipose sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thermoneutral fat signal fraction of brown adipose tissue</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>MRI measurement of lipid content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold-exposed fat signal fraction of white adipose tissue and grown adipose tissue</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>MRI measurement of lipid content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous adipose tissue gene expression of mitochondrial genes (normalized expression units)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Measurement of gene expression in adipose sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous adipose tissue natriuretic peptide receptor expression</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Measurement of gene expression in adipose sample</description>
  </secondary_outcome>
  <other_outcome>
    <measure>BAT perfusion under thermoneutral and cold conditions</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>MRI measurement of blood flow</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in BNP concentration during cold exposure</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Blood measurement of hormone</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in free fatty acid level during cold exposure</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Blood measurement of fat</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in whole body subcutaneous and visceral fat mass</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Measurement of fat mass will be examined using dual x-ray absorptiometry to assess for changes in fat mass.</description>
  </other_outcome>
  <other_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>Baseline to 12 Weeks</time_frame>
    <description>Measurement of energy expended</description>
  </other_outcome>
  <other_outcome>
    <measure>Homeostatic Index of Insulin Resistance</measure>
    <time_frame>Baseline to 12 Weeks</time_frame>
    <description>Blood measurement of insulin resistance</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: screening visit, baseline visit, an interim visit (10 weeks post-baseline), and a 12-week visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: screening visit, baseline, an interim visit (10 weeks post-baseline), and a 12-week visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 20 MG</intervention_name>
    <description>Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.</description>
    <arm_group_label>Tadalafil</arm_group_label>
    <other_name>CIALIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults&#xD;
&#xD;
          -  Obesity (BMI â‰¥ 30 kg/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;19 or &gt; 50&#xD;
&#xD;
          -  BMI &lt; 30 kg/m2&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &lt; 100, &gt; 150 mmHg&#xD;
&#xD;
          -  Current anti-hypertensive medication use, including diuretics&#xD;
&#xD;
          -  Current use of organic nitrates&#xD;
&#xD;
          -  Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)&#xD;
&#xD;
          -  History of reaction to PDE-5 inhibitors&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Use of medications that strongly alter CYP3A4 activity&#xD;
&#xD;
          -  History of myocardial infarction, angina, uncontrolled cardiac arrhythmia, stroke,&#xD;
             transient ischemic attack, or seizure&#xD;
&#xD;
          -  Known non-arteritic ischemic optic retinopathy (NAIOR)&#xD;
&#xD;
          -  History of hearing loss&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73 m2 by the modified diet&#xD;
             in renal disease (MDRD) equation&#xD;
&#xD;
          -  Hepatic transaminase (AST and ALT) levels greater than three times the upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Known pregnancy or breastfeeding or those unwilling to avoid pregnancy during the&#xD;
             course of the study&#xD;
&#xD;
          -  History of priapism&#xD;
&#xD;
          -  Use in excess of four alcoholic drinks daily&#xD;
&#xD;
          -  History of diabetes mellitus or use of anti-diabetic medications&#xD;
&#xD;
          -  Known anemia (men, Hct &lt; 38% and women, Hct &lt;36%)&#xD;
&#xD;
          -  Menopause&#xD;
&#xD;
          -  Weight &gt; 300 pounds&#xD;
&#xD;
          -  Individuals with circadian rhythm disorders, shift workers, or those who travel across&#xD;
             time zones frequently&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Brittain, MD, MSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>VUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rashundra Oggs, NP</last_name>
    <phone>615-875-7975</phone>
    <email>rashundra.n.oggs@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evan Brittain, MD, MSci</last_name>
    <phone>615-322-4382</phone>
    <email>Evan.brittain@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Evan Brittain</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

